Related Experiment Videos

Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures

William R Wilson1, Susan M Pullen, Alison Hogg

  • 1Auckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland, New Zealand. wr.wilson@auckland.ac.nz

Cancer Research
|March 13, 2002
PubMed

Insights

Cancer gene therapy relies on bystander effects, where modified tumor cells kill nearby unmodified cells. A new 3D model accurately quantifies these effects, identifying a potent prodrug for enhanced cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Cancer gene therapy efficacy is enhanced by bystander effects, where modified tumor cells induce death in adjacent unmodified cells.
  • Enzyme-prodrug therapy utilizes suicide genes to activate prodrugs, generating cytotoxic metabolites that diffuse to kill neighboring cancer cells.

Purpose of the Study:

  • To develop a physiologically relevant 3D tissue culture model for quantifying cancer gene therapy bystander effects.
  • To validate the model using Escherichia coli aerobic nitroreductase (NTR) mediated activation of dinitrobenzamide prodrugs.
  • To identify novel prodrugs with improved therapeutic potential.

Main Methods:

  • Utilized three-dimensional multilayer cocultures of NTR-expressing (NTR+) and non-expressing (NTR-) cells (V79, Skov3, WiDr).
  • Quantified bystander effects by determining clonogenic survival curves for both cell types.
  • Correlated in vitro bystander killing with in vivo xenograft data.

Main Results:

  • Bystander killing was significantly more efficient in 3D multilayers compared to 2D monolayers.
  • Prodrug lipophilicity positively correlated with bystander killing efficiency in the multilayer model.
  • The model identified a bromomustard prodrug (SN 24927) with superior efficacy to CB 1954, achieving curative activity in mixed cell tumors.

Conclusions:

  • The developed 3D multilayer model is effective for quantifying and optimizing bystander effects in cancer gene therapy.
  • This model facilitated the identification of SN 24927 as a promising lead prodrug for NTR gene-dependent enzyme-prodrug therapy.
  • The findings support the advancement of enzyme-prodrug strategies for improved cancer treatment outcomes.

Related Concept Videos